NASDAQ:OVID
Ovid Therapeutics Inc.
Ovid Therapeutics Inc.'s revenue grew 1181.3% in fiscal 2025 to $7.3M while operating margin rose to −585.2%. Free cash flow was −$38.3M, −528.6% of revenue.Summary generated from Ovid Therapeutics Inc.'s SEC filings. Latest annual report filed Mar 18, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$7.3M
Revenue growth+1181.3%
Revenue, 5-yr CAGR−10.5%
Gross marginn/a
Operating margin−585.2%
Net margin−240.1%
ROICn/a
Return on equity−17.5%
Debt / equityn/a
Free cash flow−$38.3M
FCF margin−528.6%
Share count changen/a
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 208 | 2 | 0 | 1 | 7 |
| Operating income | 124 | −56 | −59 | −62 | −42 |
| Net income | 123 | −54 | −52 | −26 | −17 |
| Free cash flow | 118 | −56 | −46 | −56 | −38 |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KCurrent report
Aug 13, 2026 - 4Insider transaction report
Jul 8, 2026 - 8-KDirector or officer change
Jul 8, 2026 - 4Insider transaction report
Jun 17, 2026 - 8-KResults of a shareholder vote
Jun 11, 2026 - 8-KDirector or officer change
Jun 3, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 12, 2026